Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Dabomb Protein Biotech's annualized net income for the quarter that ended in Dec. 2025 was NT$-177.2 Mil. Dabomb Protein Biotech's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,007.7 Mil. Therefore, Dabomb Protein Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -17.58%.
The historical rank and industry rank for Dabomb Protein Biotech's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6578'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.1 Med: 1.09 Max: 11.3
Current: -6.63
During the past 13 years, Dabomb Protein Biotech's highest Return-on-Tangible-Equity was 11.30%. The lowest was -9.10%. And the median was 1.09%.
ROCO:6578's Return-on-Tangible-Equity is ranked worse than 84.31% of 1880
companies
in the Consumer Packaged Goods industry
Industry Median: 7.795
vs ROCO:6578: -6.63
Dabomb Protein Biotech (ROCO:6578) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Dabomb Protein Biotech Return-on-Tangible-Equity Related Terms
Dabomb Protein Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Dabomb Protein Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech Return-on-Tangible-Equity Chart
ROCO:6578 vs KHC, GIS: Return-on-Tangible-Equity Comparison
For the Packaged Foods subindustry, Dabomb Protein Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Return-on-Tangible-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -17.58% mean?
Dabomb Protein Biotech (ROCO:6578) has a Return-on-Tangible-Equity of -17.58% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dabomb Protein Biotech and its competitors. According to the industry distribution chart, Dabomb Protein Biotech ranks #1585 out of 1880 companies in the Consumer Packaged Goods industry, placing it in the top 84.3%.
Is Dabomb Protein Biotech's Return-on-Tangible-Equity too high?
Dabomb Protein Biotech's current Return-on-Tangible-Equity is -17.58%. Based on the distribution chart, Dabomb Protein Biotech ranks #1585 out of 1880 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Return-on-Tangible-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #1585 out of 1880 companies for Return-on-Tangible-Equity. This places Dabomb Protein Biotech in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Consumer Packaged Goods company?
The median Return-on-Tangible-Equity among Consumer Packaged Goods companies is 7.80, based on 1,880 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Return-on-Tangible-Equity is -17.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.44, compared to a current price of NT$16.20 — trading 12.2% above its estimated fair value. The current Return-on-Tangible-Equity is -17.58%. Dabomb Protein Biotech's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Return-on-Tangible-Equity is -17.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.20 is trading 12.2% above its estimated GF Value™ of NT$14.44.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
Return-on-Tangible-Equity: -17.58%
GF Value™: NT$14.44 vs. price of NT$16.20 (12.2% above fair value)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
58GF Score
Get the complete analysis for ROCO:6578
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
